Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17256399 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL30915198 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL31121260 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL29702364 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL30621106 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2607961 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL12107853 | 1.00 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL18084278 | 0.99 | HPGD (0.44) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL14701712 | 0.97 | HPGD (0.41) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL14701730 | 0.94 | HPGD (0.41) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626462-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | Fundació Hospital Universitari Vall Hebron - Institut de Recerca (ES) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115612-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR) (ES) | 2024-06-06 | — | — | WO | disclosed |
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360951-A1 | BIOLOGICAL MATERIALS AND USES THEREOF | CD47, LNPEP, TIE1 | HPGD 3338/4885SMN1; SMN2 3169/4885NPC1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.